Why Exact Sciences Stock Blasted Higher on Tuesday
Cancer screening and diagnostics specialist Exact Sciences (NASDAQ: EXAS) was a standout stock on the second trading day of the week. Eager investors piled into it to leave it with a nearly 4% gain in price over the trading session, on a day when the S&P 500 (SNPINDEX: ^GSPC) suffered a 1.2% decline.
Just after market close on Monday, Exact Sciences took the wraps off its third-quarter performance. Its revenue for the period set a new record at $851 million, for a robust 20% year-over-year increase. This was also well above the average analyst estimate of less than $811 million.
Image source: Getty Images.
Source Fool.com
